Watch-and-wait OK in low-tumor burden follicular lymphoma

September 26, 2012
Watch and wait OK in low-tumor burden follicular lymphoma
An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared with patients initially treated with rituximab-containing regimens, according to research published online Sept. 24 in the Journal of Clinical Oncology.

(HealthDay)—An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared with patients initially treated with rituximab-containing regimens, according to research published online Sept. 24 in the Journal of Clinical Oncology.

Philippe Solal-Céligny, M.D., Ph.D., of the Institut de Cancérologie de l'Ouest in Saint Herblain, France, and colleagues conducted a involving 120 patients with treatment-naive follicular lymphoma who were initially managed expectantly and 107 comparator patients. The majority of patients (80 percent) had a low tumor burden and disseminated disease.

Treatment was initiated in half of the patients after a median follow-up period of 64 months. After adjusting for potential confounders, the researchers found that patients with more than four nodal areas affected were 2.32-fold more likely to have a shorter time to initiation. Overall, watch-and-wait patients had a four-year FFTF rate of 79 percent, compared with 69 percent for those who were initially treated with a rituximab-containing regimen.

"Our data in a prospective and well-analyzed database that reflects actual practice suggest that there is no difference in outcome between patients who were observed and patients who were treated initially," the authors write. "Our cohort study provides additional information relevant to the important issue of management of patients with follicular lymphoma in the current era and suggests that observation remains an appropriate approach in asymptomatic patients with low-tumor burden ."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Autologous stem cell transplantation does not improve os in patients with follicular lymphoma

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

R-CHOP benefits older mantle-cell lymphoma patients

August 9, 2012

(HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintenance therapy with rituximab ...

Recommended for you

Cancer hijacks natural cell process to survive

June 26, 2017

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

Targeted drug shows promise in rare advanced kidney cancer

June 23, 2017

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.